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Malignant diseases present a significant burden to healthcare systems worldwide, the 
major types of cancers are the leading causes of death among the 18-64-year-old population 
[1,2]
. The mortality associated with lung and colorectal cancer amid the EU countries is the 
highest in Hungary.
[3]
 Combination chemotherapy as a viable treatment of various 
malignancies has been described in the clinical practice as well as in a research setting. The 
additional problem of cancer multidrug resistance (MDR) and tumour cell heterogeneity 
further confirms the relevance of multiple drug treatment.
[4]
 The activity of urea, thiourea 
and selenourea derivatives against various cancer cell lines has been demonstrated by the 
literature.
[5]
 
The aim of our study was to evaluate the efficacy of novel urea and thiourea 
derivatives (1-10) as anticancer agents in combination chemotherapy, using various in vitro 
model systems. 
 
Figure 1.: General structure of the tested compounds (1-10) 
 
 
The antiproliferative and cytotoxic activity of the compounds against tumoral and 
non-cancerous cell lines was assessed by MTT method, the inhibition of the MDR 
transporter P-glycoprotein (ABCB1) was studied by rhodamine 123 accumulation assay 
using flow cytometry 
[6,7]
. A checkerboard microplate method was applied to evaluate the 
effect of drug interactions between the tested compounds and the reference drugs 
(doxorubicin, cisplatin, 5-fluorouracil, topotecan, methotrexate and verapamil), the 
interactions were categorized based on combination index (CI) values, using the Chou-
Talalay method 
[8]
. 
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Figure 2.: Setup of the plates in the checkerboard combination assay 
 
 
Apart from a benzyl-substituted thiourea-derivative, the tested compounds did not 
present potent cytotoxicity, while all derivatives showed moderate antiproliferative activity 
in the concentration range of 11.9-90.5 µM. The compounds were slightly selective towards 
the tumoral cell lines. The tested compounds did not show effectual efflux pump inhibitory 
activity in the tested concentrations. Some of the (thio)ureas showed favourable interactions 
with 5-fluorouracil (pyrimidine-antagonist) and verapamil (efflux pump inhibitor), while 
strong synergism was observed in relation to topotecan (topoisomerase-I-inhibitor) and 
doxorubicin (topoisomerase-II-inhibitor). In contrast, in case of cisplatin (alkylating agent) 
and methotrexate (folate-antagonist), antagonism was predominantly observed. 
While the tested compounds did not show remarkable anticancer and efflux pump 
inhibitory activity, the ureas/thioureas presented potent synergistic activities with the 
anticancer drugs acting on the topoisomerase enzymes. The design of further experiments 
and the involvement of additional chemotherapeutic drugs are warranted to fully assess 
their potency as adjuvants. 
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